» Articles » PMID: 17911173

Lack of Mutations in the Thyroid Hormone Receptor (TR) Alpha and Beta Genes but Frequent Hypermethylation of the TRbeta Gene in Differentiated Thyroid Tumors

Overview
Specialty Endocrinology
Date 2007 Oct 4
PMID 17911173
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Context: It remains inconclusive whether mutations in thyroid hormone receptor (TR) genes naturally occur in thyroid cancer and whether these genes could be suppressors of this cancer.

Objectives: Our objectives were to examine further mutations of TRalpha and TRbeta genes in thyroid cancer and also to examine their methylation as an epigenetic silencing mechanism in thyroid cancer.

Experimental Design: Instead of using a cDNA sequencing approach used in previous studies, we used genomic DNA to sequence directly the coding regions of the TRalpha and TRbeta genes to search mutations in various differentiated thyroid tumors and used methylation-specific PCR to analyze promoter methylation of these genes. Allelic zygosity status at TRbeta was also analyzed.

Results: We found no TRalpha gene mutation in 17 papillary thyroid cancers (PTCs) and 11 follicular thyroid cancers (FTCs), and no TRbeta gene mutation in 16 PTCs and 12 FTCs. We also found no methylation of the TRalpha gene in 33 PTCs, 31 FTCs, 20 follicular thyroid adenomas (FTAs), and 10 thyroid tumor cell lines. In contrast, we found hypermethylation of the TRbeta gene in 10 of 29 (34%) PTCs, 22 of 27 (81%) FTCs, five of 20 (25%) follicular thyroid adenomas, and three of 10 (30%) thyroid tumor cell lines, with the highest prevalence in FTC. We additionally examined loss of heterozygosity at TRbeta and found it in three of nine (33%) PTCs and three of nine (33%) FTCs.

Conclusions: Mutation is not common in TR genes, whereas hypermethylation of the TRbeta gene as an alternative gene silencing mechanism is highly prevalent in thyroid cancer, particularly FTC, consistent with a possible tumor suppressor role of this gene for FTC.

Citing Articles

From maternal glucocorticoid and thyroid hormones to epigenetic regulation of offspring gene expression: An experimental study in a wild bird species.

Hukkanen M, Hsu B, Cossin-Sevrin N, Crombecque M, Delaunay A, Hollmen L Evol Appl. 2023; 16(10):1753-1769.

PMID: 38020869 PMC: 10660793. DOI: 10.1111/eva.13598.


Reactivated thyroid hormone receptor β attenuates anaplastic thyroid cancer (ATC) stem cell activity.

Zhu X, Zhao L, Doolittle W, Cheng S Endocr Relat Cancer. 2023; 30(6).

PMID: 36939877 PMC: 10354538. DOI: 10.1530/ERC-22-0306.


Regulation of cancer stem cell activity by thyroid hormone receptor β.

Doolittle W, Zhu X, Park S, Zhu Y, Zhao L, Meltzer P Oncogene. 2022; 41(16):2315-2325.

PMID: 35256781 PMC: 9018601. DOI: 10.1038/s41388-022-02242-9.


Targeting transcriptional regulators for treatment of anaplastic thyroid cancer.

Lee W, Cheng S J Cancer Metastasis Treat. 2021; 7.

PMID: 34761120 PMC: 8577520. DOI: 10.20517/2394-4722.2021.58.


Thyroid Hormone Receptor Beta as Tumor Suppressor: Untapped Potential in Treatment and Diagnostics in Solid Tumors.

Davidson C, Gillis N, Carr F Cancers (Basel). 2021; 13(17).

PMID: 34503062 PMC: 8428233. DOI: 10.3390/cancers13174254.